MAP Pharmaceuticals

Map Pharmaceuticals

Pharmaceuticals, 2400 Bayshore Pkwy, Mountain View, California, 94043, United States, 51-200 Employees

mappharma.com

  • LinkedIn

phone no Phone Number: +16*********

Who is MAP PHARMACEUTICALS

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. T...

Read More

map
  • 2400 Bayshore Pkwy, Mountain View, California, 94043, United States Headquarters: 2400 Bayshore Pkwy, Mountain View, California, 94043, United States
  • 2005 Date Founded: 2005
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 3841 | NAICS Code: 339113 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from MAP PHARMACEUTICALS

MAP Pharmaceuticals Org Chart and Mapping

Employees

Wayne Bliss

Shipping & Receiving Specialist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding MAP Pharmaceuticals

Answer: MAP Pharmaceuticals's headquarters are located at 2400 Bayshore Pkwy, Mountain View, California, 94043, United States

Answer: MAP Pharmaceuticals's phone number is +16*********

Answer: MAP Pharmaceuticals's official website is https://mappharma.com

Answer: MAP Pharmaceuticals's revenue is $25 Million to $50 Million

Answer: MAP Pharmaceuticals's SIC: 3841

Answer: MAP Pharmaceuticals's NAICS: 339113

Answer: MAP Pharmaceuticals has 51-200 employees

Answer: MAP Pharmaceuticals is in Pharmaceuticals

Answer: MAP Pharmaceuticals contact info: Phone number: +16********* Website: https://mappharma.com

Answer: MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEXTM inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access